3.0SEK
91.82 MSEK
597.54 MSEK
24.21 M
About XVIVO PERFUSION AB
Sector
Industry
CEO
Christoffer Rosenblad
Website
Headquarters
Gothenburg
Employees (FY)
150
Founded
1998
ISIN
SE0004840718
FIGI
BBG003FHC7K8
Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of XVIVO is 321.0 SEK — it has decreased by 2.13% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange XVIVO PERFUSION AB stocks are traded under the ticker XVIVO.
XVIVO PERFUSION AB is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
XVIVO stock is 3.47% volatile and has beta coefficient of 0.89. Check out the list of the most volatile stocks — is XVIVO PERFUSION AB there?
One year price forecast for XVIVO PERFUSION AB has a max estimate of 439.0 SEK and a min estimate of 340.0 SEK.
XVIVO earnings for the last quarter are 0.10 SEK whereas the estimation was 0.43 SEK which accounts for −76.91% surprise. Estimated earnings for the next quarter are 0.47 SEK. See more details about XVIVO PERFUSION AB earnings.
XVIVO PERFUSION AB revenue for the last quarter amounts to 146.61 M SEK despite the estimated figure of 156.40 M SEK. In the next quarter revenue is expected to reach 173.36 M SEK.
Yes, you can track XVIVO PERFUSION AB financials in yearly and quarterly reports right on TradingView.
XVIVO stock has risen by 12.43% compared to the previous week, the month change is a 16.52% rise, over the last year XVIVO PERFUSION AB has showed a 25.15% increase.
XVIVO net income for the last quarter is 68.47 M SEK, while the quarter before that showed 2.28 M SEK of net income which accounts for 2.90 K% change. Track more XVIVO PERFUSION AB financial stats to get the full picture.
Today XVIVO PERFUSION AB has the market capitalization of 10.33 B, it has increased by 6.75% over the last week.
No, XVIVO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, XVIVO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XVIVO PERFUSION AB stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 150.00 employees. See our rating of the largest employees — is XVIVO PERFUSION AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XVIVO PERFUSION AB technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XVIVO PERFUSION AB stock shows the strong buy signal. See more of XVIVO PERFUSION AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on XVIVO PERFUSION AB future price: according to them, XVIVO price has a max estimate of 439.00 SEK and a min estimate of 340.00 SEK. Read a more detailed XVIVO PERFUSION AB forecast: see what analysts think of XVIVO PERFUSION AB and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XVIVO PERFUSION AB EBITDA is 78.27 M SEK, and current EBITDA margin is 11.61%. See more stats in XVIVO PERFUSION AB financial statements.